KKR closes $5.9B Integer Holdings buy as healthcare deal count climbs in August downdraft

KKR & Co. closed its $5.89 billion acquisition of Integer Holdings in August, a medical device manufacturer with exposure to cardiac rhythm management and neuromodulation segments. The deal anchored a month in which overall private equity transaction volume fell sharply across regions, yet healthcare assets pulled disproportionate allocator attention. Integer's revenue base is $1.6 billion annually, serving OEM contracts with established cardiac and surgical device platforms.

Global private equity deal count dropped in August, reflecting the lag effects of higher cost of capital and delayed exit windows. Healthcare transactions, however, moved counter to the broader trend. KKR's Integer acquisition was the largest healthcare buyout of the month, representing nearly half of disclosed healthcare PE volume in the period. The firm structured the deal at a reported 13.2x trailing EBITDA, a multiple that sits above the sector's recent twelve-month median of 11.7x but reflects the scarcity value of scaled medical device platforms with durable OEM relationships. Integer's manufacturing footprint spans five countries, and 68% of its revenue derives from cardiac applications, a segment with structural tailwinds as patient populations age and device upgrade cycles shorten.

The resilience of healthcare deal activity in a contracting environment signals two dynamics worth isolating. First, strategic and financial buyers continue to compete for assets with predictable cash conversion and regulatory moats, even as broader industrials and consumer plays sit in extended diligence. Second, KKR's willingness to deploy $5.9 billion in a single healthcare platform reflects a view that device manufacturing—particularly in cardiac and neuro applications—will produce IRRs above the firm's 15% minimum hurdle despite elevated entry multiples. That calculation hinges on Integer's ability to expand margins through operational consolidation and to capture incremental volume as its OEM customers push new product cycles. The firm has historically exited healthcare holdings within a four-to-six year window, suggesting a 2028–2030 timeline for liquidity, likely through a sale to a larger medtech consolidator or a carve-out IPO if public markets recover.

Allocators should track three follow-on signals. First, whether KKR initiates add-on acquisitions to fold smaller device manufacturers into Integer's platform within the next six to nine months, a pattern the firm has repeated in prior healthcare rollups. Second, monitor Integer's OEM contract renewals with its top three customers, which represent 42% of revenue and come up for negotiation in Q1 and Q3 2025. Third, watch for competing bids on mid-cap healthcare services and device assets in Q4, as the Integer close may pull forward other PE firms' deployment timelines to avoid missing the cycle.

The deal cleared regulatory review without meaningful delay, and Integer's management team remains in place. KKR's healthcare vertical now holds $28 billion in committed capital across 17 platform companies, the largest concentration in its fund portfolio.